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Abstract
Stress-related cardiomyopathies can be observed in the four following situations: Takotsubo cardiomyopathy or
apical ballooning syndrome; acute left ventricular dysfunction associated with subarachnoid hemorrhage; acute left
ventricular dysfunction associated with pheochromocytoma and exogenous catecholamine administration; acute
left ventricular dysfunction in the critically ill. Cardiac toxicity was mediated more by catecholamines released
directly into the heart via neural connection than by those reaching the heart via the bloodstream. The
mechanisms underlying the association between this generalized autonomic storm secondary to a life-threatening
stress and myocardial toxicity are widely discussed. Takotsubo cardiomyopathy has been reported all over the
world and has been acknowledged by the American Heart Association as a form of reversible cardiomyopathy.
Four “Mayo Clinic” diagnostic criteria are required for the diagnosis of Takotsubo cardiomyopathy: 1) transient left
ventricular wall motion abnormalities involving the apical and/or midventricular myocardial segments with wall
motion abnormalities extending beyond a single epicardial coronary artery distribution; 2) absence of obstructive
epicardial coronary artery disease that could be responsible for the observed wall motion abnormality; 3) ECG
abnormalities, such as transient ST-segment elevation and/or diffuse T wave inversion associated with a slight
troponin elevation; and 4) the lack of proven pheochromocytoma and myocarditis. ECG changes and LV
dysfunction occur frequently following subarachnoid hemorrhage and ischemic stroke. This entity, referred as
neurocardiogenic stunning, was called neurogenic stress-related cardiomyopathy. Stress-related cardiomyopathy
has been reported in patients with pheochromocytoma and in patients receiving intravenous exogenous
catecholamine administration. The role of a huge increase in endogenous and/or exogenous catecholamine level
in critically ill patients (severe sepsis, post cardiac resuscitation, post tachycardia) to explain the onset of myocardial
dysfunction was discussed. Further research is needed to understand this complex interaction between heart and
brain and to identify risk factors and therapeutic and preventive strategies.
Introduction
Neurocardiology has many dimensions, namely divided
in three categories: the heart’s effects on the brain (i.e.,
embolic stroke); the brain’s effects on the heart (i.e.,
neurogenic heart disease); and neurocardiac syndromes,
such as Friedreich disease [1]. The present review will
focus on the nervous system’s capacity to injure the
heart. The relationship between the brain and the heart,
i.e., the brain-heart connection, is central to maintain
normal cardiovascular function. This relationship con-
cerns the central and autonomic nervous systems, and
their impairment can adversely affect cardiovascular sys-
tem and induce stress-related cardiomyopathy (SRC) [2].
Even if it is unclear whether myocardial adrenergic
stimulation is the only pathophysiological mechanism
associated with SRC, enhanced sympathetic tone indu-
cing endogenous catecholamine’s stimulation of the
myocardium was always reported [3].
The first description of suspected SRC was reported
by W.B. Cannon in 1942 cited by Engel et al. [4] who
published a paper entitled “Voodoo death,” which
reported anecdotal experiences of death from fright.
This author postulated that death can be caused by an
intense action of the sympathico-adrenal system. In
1971, Engel et al. collected more than 100 accounts
from the lay press of sudden death attributed to stress
associated with disruptive life events and provided a
window into the world of neurovisceral disease (i.e., psy-
chosomatic illness).
It is now widely admitted that this autonomic storm,
which results from a life-threatening stressor, can be
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ventricle (LV) dysfunction [2]:
- Takotsubo cardiomyopathy or apical ballooning syn-
drome [5]
- Acute LV dysfunction associated with subarachnoid
hemorrhage [6]
- Acute LV dysfunction associated with pheochromo-
cytoma and exogenous catecholamine administration [7]
- Acute LV dysfunction in the critically ill [8]
Brain-heart connection
Emotional and physical stress can induce an excitation
of the limbic system. Amygdalus and hippocampus are,
with the insula the principle brain areas, implicated in
emotion and memory [9,10]. These areas play a central
role in the control of cardiovascular function [9,10].
Their excitation provokes the stimulation of the medul-
lary autonomic center, and then the excitation of pre-
and post-synaptic neurons leading to the liberation of
norepinephrine and its neuronal metabolites [11]. Adre-
nomedullary hormonal outflows increase simultaneously
and induce the liberation of epinephrine. Epinephrine
released from the adrenal medulla and norepinephrine
from cardiac and extracardiac sympathetic nerves reach
heart and blood vessel adrenoreceptors [1,9,10]. The
occupation of the cardio-adrenoreceptors induces cate-
cholamine toxicity in the cardiomyocytes [11].
Wittstein et al. compared plasma catecholamine levels
in patients with SRC to those observed in patients with
Killip class III myocardial infarction [3]. They reported a
neurally induced exaggerated sympathetic stimulation in
patients with SRC [3]. Thus a significant increase in
plasma epinephrine, norepinephrine, dihydroxyphenyla-
lanine, dihydroxyphenylglycol, and dihydroxyphenylace-
tic acid was observed and was consistent with the
presence of enhanced catecholamine synthesis, neuronal
reuptake, and neuronal metabolism, respectively [3]
(Table 1). A significant increase in neuropeptide Y,
which is stored in postganglionic sympathetic nerves,
was observed in patients with SRC. By contrast the
increase in plasma levels of metanephrine and normeta-
nephrine, which are extra neuronal catecholamine meta-
bolites, was within a similar range to that observed in
Killip class III myocardial infarction patients [3]. This
finding suggests that cardiac toxicity was mediated more
by catecholamines released directly into the heart via
neural connection than by those reaching the heart via
the bloodstream.
The mechanisms underlying the association between
this generalized autonomic storm secondary to a life-
threatening stress and myocardial toxicity are widely dis-
cussed. Three mechanisms have been reported. Some
authors have suggested that multivessel epicardial cor-
onary artery spasm could supervene, but angiographic
evidence of epicardial spasm was not reported by Witt-
stein et al. [3]. Coronary microvascular impairment
resulting in myocardial stunning was suspected by some
authors [12]. The most widely accepted mechanism of
catecholamine mediated myocardial stunning is direct
myocardial toxicity [13]. Catecholamines can decrease
the viability of cardiomyocytes through cyclic AMP-
mediated calcium overload and oxygen-derived free
radicals [14]. This hypothesis was sustained by the myo-
cardial histological changes observed in heart from
patients suffering from SRC [1]. These histological
changes are the same that those observed following high
doses catecholamine infusion in animals. These changes
differ from those observed in ischemic cardiac necrosis.
Contraction band necrosis, neutrophil infiltration, and
fibrosis reflecting high intracellular concentrations of
calcium are generally observed [1]. It is now generally
assumed that this calcium overload produces the ventri-
cular dysfunction in catecholamine cardiotoxicity. The
low incidence of the onset of these SRC and their
description frequently reported in postmenopausal
women suggested the possibility of a genetic predisposi-
tion [15,16]. Thus, Spinelli et al. evaluated the incidence
of common polymorphisms of beta 1 and beta 2 adre-
nergic receptors, the Gs to which the receptors are
coupled and GRK5 which desensitizes them [16]. They
observed that the GRK5 Leu41 polymorphism was sig-
nificantly more common in SRC than in a control group
and suggested that this polymorphism was associated
with an enhanced beta adrenergic desensitization which
may predispose to cardiomyopathy caused by repetitive
catecholamine surges [15,16].
Table 1 Plasma catecholamine levels in 13 patients with stress-related cardiomyopathy (Takotusbo) compared to 7
patients with Killip Class III myocardial infarction
Catecholamines
(pg/ml)
Takotusbo
(n = 13)
Infarctus Killip III
(n = 7)
p Normal value
Dihydroxyphénylalanine 2859 (2721- 2997) 1282 (1124-1656) < 0.05 1755
Epinephrine 1264 (916-1374) 376 (275- 476) < 0.05 37
Norepinephrine 2284 (1709-2910) 1100 (914- 1320) < 0.05 169
Dopamine 111 (106- 146) 61 (46-77) < 0.05 15
Median and interquartile range (25-75%). Mann-Whitney test. From reference (3) with permission.
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Takotsubo cardiomyopathy or apical ballooning
syndrome
Japanese authors reported in the nineties the first cases
of reversible cardiomyopathy precipitated by acute and
severe emotional stress in postmenopausal women
[11,17-20]. This SRC was characterized by the onset of
an acute coronary syndrome associated with a specific
and reversible apical and wall motion abnormality
despite the lack of coronary artery disease [11]. Initially,
this syndrome was given the name Takotsubo cardio-
myopathy and was secondarily referred to as the apical
ballooning syndrome and broken heart disease
[11,17-20]. The name Takotsubo was taken from the
Japanese name for an octopus trap, which mimics the
typical apical ballooning aspect of the left ventricle dur-
ing the systole (Figure 1). Takotsubo has been reported
all over the world and has been acknowledged by the
American Heart Association and the American College
of Cardiology as a form of reversible cardiomyopathy
[21,22]. It has been estimated that 4-6% of women pre-
senting with acute coronary syndrome suffered from
Takotsubo [21].
Usually seen in postmenopausal women, the clinical
presentation of Takotsubo is similar to that of an acute
coronary syndrome with typical chest pain and ECG
abnormalities. Reported emotional stress included for
example death of a family member, traffic road acci-
dents, financial loss, and disasters, such as earthquakes
[5,23,24]. In some patients, no clear precipitating factor
can be identified. ST segment elevation on the ECG was
observed in the majority of cases (Figure 2). Twenty-
four to 40 hours later, T wave inversion supervened and
q waves were seen in one third of the patients. Thus,
there are no ECG criteria to discriminate between
Takotsubo and acute myocardial infarction [5,23,24].
The elevation in troponin is very limited far from the
huge increase observed during myocardial infarction. A
very low incidence of in hospital mortality was reported,
and heart failure, cardiogenic shock, and ventricular
arrhythmias are observed in a minority of patients
[11,17,23,25].
Typically, echocardiography showed apical and mid-
ventricular wall motion abnormalities and hyperkinesis
of the basal myocardial segments [2]. These wall motion
abnormalities did not correspond to a single epicardial
coronary distribution. Apical and midventricular wall
motion abnormalities can induce a dynamic obstruction
in the LV outflow associated with a systolic anterior
motion of the mitral leaflet.
When performed, LV angiography confirmed these
wall motion abnormalities (Figure 3) with the classical
aspect of Takotsubo. Coronary angiography revealed
the absence of obstructive epicardial coronary artery
disease. Scintigraphic imaging and cardiac magnetic
resonance imaging failed to reveal myocardial necro-
sis. Late gadolinium enhancement during cardiac mag-
netic resonance was absent eliminating ischemic
myocardial necrosis [2]. Cardiac positron emission
tomography using 18-fluorodeoxyglucose suggested an
aspect of metabolic stunned myocardium associated
with catecholamine excess. This stunned myocardium
could be the consequence either of an intramyocardial
calcium overload or ischemic-reperfusion phenomena
[12-14].
Many morphological LV variants of Takotsubo have
been reported: isolated midventricular and basal dys-
function with apical sparing, isolated basal hypokinesis,
named inverse Takotsubo [11,26]. The reason for this
noncoronary distribution of the segmental wall motion
abnormalities was unknown and often related to differ-
ences in myocardial autonomic innervation and adrener-
gic stimulation [2,3,18].
Bybee and Prasad suggested four “Mayo Clinic” diag-
nostic criteria for Takotsubo: 1) transient LV wall
motion abnormalities involving the apical and/or mid-
ventricular myocardial segments with wall motion
Figure 1 The name Takotsubo was taken from the Japanese
name for an octopus trap, which mimics the typical apical
ballooning aspect of the left ventricle during the systole.
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onary artery distribution; 2) absence of obstructive epi-
cardial coronary artery disease that could be responsible
for the observed wall motion abnormality; 3) ECG
abnormalities, such as transient ST-segment elevation
and/or diffuse T-wave inversion associated with a slight
troponin elevation; and 4) the lack of proven pheochro-
mocytoma and myocarditis [2].
Patients with suspected and/or proved Takotsubo
must be monitored in intensive care. Because massive
catecholamine release was observed in Takotsubo-
induced stunned myocardium, beta agonists and vaso-
pressors might be avoided whenever possible even in
acute circulatory failure and mechanical circulatory sup-
port preferred if necessary. Sympathetic activation sug-
gested the use of beta blocker therapy as soon as LV
failure was corrected. The presence of a dynamic
obstruction in the LV outflow precluded the initiation
of an angiotensin-converting enzyme inhibitor, angioten-
sin receptor blocker, or diuretic treatment because of a
possible potentiation. Anticoagulation with heparin was
required to prevent left ventricle thrombus formation
[18,24,27].
Echocardiographic examination will be regularly per-
formed after hospital discharge to evaluate the resolu-
tion of LV dysfunction, which is complete in the
majority of the patients after 1 to 3 months. A favorable
prognosis has been widely reported in the more recent
literature [23].
Acute LV dysfunction associated with subarachnoid
haemorrhage
ECG changes and LV dysfunction occur frequently after
subarachnoid hemorrhage and ischemic stroke. This
entity, referred as neurocardiogenic stunning, was called
neurogenic SRC [2]. Four independent predictors of
neurogenic SRC have been reported previously: severe
neurologic injury, plasma troponin increase, brain
natriuretic peptide elevation, and female gender [28].
The diagnosis of neurogenic SRC was associated with
the potential onset of fatal arrhythmias and an increased
risk of cerebral vasospasm. QT interval prolongation, ST
segment elevation, and symmetrical T-wave inversion
associated with an increase in cardiac troponin were
observed in approximately two thirds of patients with
severe subarachnoid hemorrhage [2]. As in the case of
Takotusbo, neurogenic SRC often is difficult to distin-
guish from acute myocardial infarction. A slight increase
in cardiac troponin and the onset of noncoronary dis-
tributed wall motion abnormalities suggest more a neu-
rogenic SRC than an acute myocardial infarction.
Echocardiography shows hypokinesis involving basal
and midventricular portion of the left ventricle, i.e.,
inverse Takotusbo. These findings are more usual than
those observed in patients suffering from Takotusbo.
Bybee and Prasad have suggested an algorithm for the
evaluation of patients with subarachnoid haemorrhage
and LV dysfunction associated with ECG abnormalities
[2]. Similarities exist between Takotusbo and neurogenic
Figure 2 Acute coronary syndrome with typical chest pain seen in a 62 years woman following emotional stress (death of a family
member). Typical ST segment elevation. Echocardiography showed apical and mid ventricular wall motion abnormalities and hyperkinesis of the
basal segment. Coronary angiography was normal. Cardiogenic shock supervened and needed circulatory assistance. Secondary favorable
outcome. Introduction of beta-blockers after the correction of acute heart failure.
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gests the existence of an overlap between these two
entities [3]. Neurogenic SRC also was reported in
patients with ischemic stroke and severe head trauma.
Acute LV dysfunction associated with pheochromocytoma
and exogenous catecholamine administration
LV dysfunction has been reported in the case of endo-
genous or exogenous over production of catecholamines.
Pheochromocytoma is a rare neuroendocrine tumor
located in the adrenal medulla that secretes catechola-
mines and particularly norepinephrine. Many case
reports have suggested the onset of reversible LV dys-
function mimicking neurogenic SRC and rarely Tako-
tusbo [7,26]. This LV dysfunction was reported during
the catecholamine crisis and generally resolved after the
surgical procedure [7,26]. Some case reports suggested
that the administration of inhaled and/or intravenous
exogenous catecholamines in patients with severe
asthma and bronchospasm could be involved in the
onset of transient neurogenic SRC [29]. Intracellular
myocytes calcium overload due to catecholamine
enhancement has been observed in myocardial biopsy
specimens [30].
Acute LV dysfunction in the critically ill
Acute LV failure occurs in approximately one-third to
one-half of critically ill hospitalized patients. As reported
by Chockalingam et al., determination as to whether the
LV dysfunction is the cause, effect, or a coincidental
finding has to be made and revisited periodically [8].
One of the most widely observed findings in critically ill
patients is the onset of a global LV dysfunction. In
patients with hemodynamic instability and acute circula-
tory failure, routine echocardiography is increasingly
performed to exclude valvular heart disease, pericardial
effusion, and acute coronary syndrome- related regional
wall motion abnormalities.
If a previously undiagnosed dilated cardiomyopathy is
excluded, global LV dysfunction can be partly explained
b yar e l a t i v ec o n t r i b u t i o no f direct catecholamine myo-
cardial toxicity in the following situations: tachycardia-
Figure 3 Left ventricle angiography during diastole (A) and systole (B) showing apical and mid ventricular wall motion abnormalities
and hyperkinesis of the basal segment (arrow). MRI in long axis showing that the akinetic regions are hypoenhanced and dark suggesting
the presence of viable myocardium (C). Reference after an acute myocardial infarction showing hyperenhancement indicative of necrosis. From
reference (3) with permission.
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multiorgan dysfunction, and postcardiac arrest syn-
drome. In these situations, a high incidence of myocar-
dial injury assessed by cardiac troponin I levels was
demonstrated despite the lack of acute coronary syn-
dromes on admission to the intensive care unit [31,32].
Quenot et al. demonstrated that this myocardial injury
was an independent determinant of in-hospital mortality
even when adjusted for the SAPS II score [32].
Tachycardia-induced cardiomyopathy
Tachycardia-induced cardiomyopathy has been defined
as a global systolic LV dysfunction secondary to atrial or
ventricular tachyarrhythmias that reversed with rhythm
control [33,34]. Studies in animals have suggested that
the progression and the severity of heart failure were
linked to the cadence of the heart rate, the duration of
the tachycardia, and its cause. Thyroid dysfunction, dys-
kaliemia, hypoxia, and beta1-cardiac receptor stimula-
tion may exacerbate this catecholamine storm. LV
function normalized in a few days to weeks after the
reduction of arrhythmias [33,34].
Hypertensive LV dysfunction
Mild troponin elevations, ischemic ECG changes, and
LV dysfunction can be observed in patients with uncon-
trolled hypertension, for example, in patients suffering
from neuroendocrine tumors, such as pheochromocy-
toma. Rapid blood pressure lowering was required with
vasodilators, i.e., nitroglycerin infusions and/or oral
administration of ACE inhibitors and angiotensin recep-
tor antagonists, to prevent the onset of acute LV dys-
function and cardiogenic shock [8,35,36].
Sepsis and septic shock
Myocardial dysfunction, which is characterized by tran-
sient biventricular impairment of myocardial contracti-
lity, is commonly observed in patients suffering from
severe sepsis and septic shock [37,38]. LV dysfunction
has been associated with the elevation of cardiac tropo-
nin levels and indicated a poor prognosis in septic criti-
cally ill patients [8,31,32,37,39]. This elevation of the
troponin levels occurred in the absence of flow limiting
coronary artery disease. The transient increase in the
troponin levels was probably the consequence of a loss
of cardiomyocytes membrane integrity with a subse-
quent troponin leakage [8,31,32,37,39]. The mechanisms
responsible for increase troponin levels and LV dysfunc-
tion are not clearly understood. The implication of sys-
temic inflammatory response with the liberation of
tumor necrosis factor alpha (TNF alpha) and other car-
diosuppressive cytokines, such as interleukin-6, has been
previously reported [8,31,32,37,39]. Histopathological
studies in patients with LV dysfunction and septic shock
revealed contraction band necrosis previously reported
in case of sympathetically mediated myocardial injury
[40]. Moreover during severe sepsis, oxidative stress and
oxygen free radicals could inactivate catecholamine by
an enhancement of their transformation in adreno-
chromes [41]. The production of adrenochromes
explains the loss of the vasoconstrictive effect of endo-
gen and exogen catecholamines [41]. It also could partly
explain myocardial toxicity and troponin liberation due
to the loss of integrity of the membrane of cardiomyo-
cytes [40]. This deactivation of the catecholamines sup-
presses their role in the inhibition of TNF alpha
production, which is a well-known cardiosuppressive
cytokine.
By contrast, some authors consider sepsis-induced
myocardial depression an adaptative and at least par-
tially protective process [42,43]. They have suggested
that the myocardial depression was the consequence of
the attenuation of the adrenergic response at the cardio-
myocyte level due to down-regulation of the beta adre-
nergic receptors and depression of the postreceptor
signaling pathways [42,43]. This hibernation-like state of
the cardiomyocytes during severe sepsis was probably
enhanced by neuronal apoptosis in the cardiovascular
autonomic centers and by inactivation of catecholamines
secondary to the production of reactive oxygen species
by oxidative stress [44]. This physiopathological
approach is reinforced by the potential harmful effect of
all strategies designed to enhance oxygen delivery above
supranormal values by inotropes and vasoconstrictors
[45].
Thus, to keep adrenergic stimulation of the heart at
the minimum level, some recently published papers sug-
gested a place for beta-blockers to favor the enhance-
ment of the decatecholaminization in septic critically ill
patients [42,43,46]. Obviously, the titration of an ade-
quate dosage of beta-blockers for these hemodynami-
cally unstable patients is difficult to find during the
acute phase. However, as in patients with SRC, the
administration of beta-blockers as soon as possible after
stabilization of the circulatory failure might be suggested
or at least investigated in prospective, randomized, clini-
cal studies [42,43,46]. Recent data suggest that beta-
blockers exert favorable effects on metabolism, glucose
homeostasis, and cytokine expression in patients with
severe sepsis [47]. It has been reported that septic
patients hospitalized in critical settings, previously trea-
ted with beta-blockers, have a better outcome
[37,42,43,46,47].
Postcardiac arrest myocardial dysfunction
Prengel et al. reported that severe stress, such as that
occurring with cardiac arrest and cardiopulmonary
resuscitation, activates the sympathetic nervous system
and causes a rise in plasma catecholamine concentra-
tions, which could play a role in the onset of post car-
diac arrest myocardial dysfunction [48]. This postcardiac
arrest myocardial dysfunction contributes with
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after in- and out-of-hospital cardiac arrest [48,49]. How-
ever, this myocardial dysfunction is responsive to ther-
apy and reversible, suggesting a stunning phenomenon
rather than a permanent and irreversible myocardial
injury (i.e., myocardial infarction) [50].
The time to recovery appeared to be between 24 and
48 hours and complete for a wide majority of the
patients. Laurent et al. reported that cardiac arrest sur-
vivors have reduced cardiac output 4 to 8 hours later
[50]. Cardiac output improved substantially by 24
hours and almost returned to normal by 72 hours in
patients who survived out-of-hospital cardiac arrest.
Using multivariate analysis, Laurent et al. demon-
strated that the amount of epinephrine used during
cardiopulmonary resuscitation predicted the occur-
rence of hemodynamic instability [50]. These results
confirm experimental data that suggest that epinephr-
ine potentiates myocardial dysfunction after resuscita-
tion [51]. Previous clinical studies suggest that high
doses of epinephrine infused during resuscitation may
alter the cardiac index after return of spontaneous cir-
culation and could be an independent predictor of
mortality [52]. Many experimental studies reported
that epinephrine, when administered during cardiopul-
monary resuscitation, significantly increased the sever-
ity of post resuscitation myocardial dysfunction as a
consequence of its beta1-adrenergic actions [50-52].
This result was associated with significantly greater
postresuscitation mortality. Thus, it would be appro-
priate to reevaluate epinephrine as the drug of first
choice for cardiac resuscitation.
In conclusion, SRC can occur after an acute physical
or psychological stress, subarachnoid hemorrhage, pheo-
chromocytoma crisis, acute medical illness, such as
severe sepsis, and after the administration of exogenous
catecholamine administration. The presence of contrac-
tion band necrosis in the myocardial biopsy specimen
suggests a catecholamine-mediated mechanism even if
other pathophysiological mechanisms have been sug-
gested. Further research is needed to understand this
complex interaction between heart and brain and to
identify risk factors and therapeutic and preventive
strategies.
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